What action is most appropriate if TCD velocities rise during days 3–14 after SAH and the patient is hemodynamically stable?

Escalate therapy or consider intervention to prevent delayed cerebral ischemia.

Rising transcranial Doppler velocities after aneurysmal SAH, especially in the window days 3–14, signal cerebral vasospasm and a real risk of delayed cerebral ischemia. Even if the patient is hemodynamically stable, the best move is to intensify management aimed at preventing ischemia. This typically means optimizing cerebral perfusion through careful hemodynamic augmentation (for example, maintaining euvolemia with adequate mean arterial pressure) and continuing close neurocritical monitoring. If medical optimization doesn’t control the risk or if signs of reduced cerebral perfusion develop, endovascular options such as intra-arterial vasodilators or angioplasty may be considered. Discontinuing monitoring, decreasing therapy, or simply observing would miss the window to prevent DCI, so escalation is the appropriate step.

Discontinue monitoring.

Decrease therapeutic interventions.

Only observe.

Want more questions?

All options are one-time payments.

$25.99

30 day pass for new members

All the basics to get you started

  • Ad-free experience
  • View your previous attempt history
  • Mobile app access
  • In-depth explanations
  • 30 day premium pass access
$59.99$171.99 usd

6 month DELUXE pass (most popular)

Full access FOR 6 MONTHS! & the ultimate digital PDF study guide (BONUS)

  • $171.99 usd value for $59.99! You save $106!
  • Ad-free experience
  • View your previous attempt history
  • Mobile app access
  • In-depth explanations
  • 6 months of full access
  • Ultimate digital PDF study guide included
  • Priority support
$15.99 $24.99

Ultimate digital PDF study guide

For those that prefer a more traditional form of learning

  • Available for instant download
  • Available offline
  • Hundreds of practice multiple choice questions
  • Comprehensive content
  • Detailed explanations
Image Description
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy